Immix Biopharma Inc (IMMX) — Cash Flow-to-Debt Ratio
Immix Biopharma Inc (IMMX) has a Cash Flow-to-Debt Ratio of -0.86x as of March 2026, meaning its operating cash flow of $-9.83 Million could theoretically repay -1% of its total liabilities ($11.45 Million) in one year. See IMMX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immix Biopharma Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Immix Biopharma Inc across 7 annual periods. Also explore Immix Biopharma Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Immix Biopharma Inc (2019–2025)
Year-by-year debt coverage analysis for Immix Biopharma Inc. For market capitalisation and broader financial context, see IMMX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.17x | $-23.93 Million | $11.04 Million | ▼ -44.0% |
| 2024 | -1.51x | $-14.60 Million | $9.70 Million | ▲ +50.7% |
| 2023 | -3.06x | $-11.37 Million | $3.72 Million | ▲ +27.9% |
| 2022 | -4.24x | $-7.41 Million | $1.75 Million | ▲ +46.1% |
| 2021 | -7.87x | $-1.59 Million | $202.04K | ▼ -10144.0% |
| 2020 | -0.08x | $-404.69K | $5.27 Million | ▲ +55.4% |
| 2019 | -0.17x | $-790.03K | $4.59 Million | — |